SCHEMBL213586

SCHEMBL213586

Cc1cnc(=O)[nH]c1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24549964 0.74 CHEK1 (0.34)
Flucytosine SCHEMBL24064 0.73
SCHEMBL30510082 0.73
SCHEMBL18081882 0.73
SCHEMBL7161858 0.73
SCHEMBL13338331 0.73
SCHEMBL19363733 0.73
SCHEMBL18081740 0.70 KMT2A (0.36)
SCHEMBL29795706 0.70 KMT2A (0.36)
SCHEMBL29551741 0.70 ABL1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2259 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388894-A1 METHODS OF USING CPG BINDING PROTEINS IN MAPPING MODIFIED CYTOSINE NUCLEOTIDES ILLUMINA, INC. (US) 2025-12-25 US claimed
EP-4594343-A1 METHODS OF USING CPG BINDING PROTEINS IN MAPPING MODIFIED CYTOSINE NUCLEOTIDES Illumina, Inc. (US) 2025-08-06 EP claimed
EP-4594481-A1 HELICASE-CYTIDINE DEAMINASE COMPLEXES AND METHODS OF USE Illumina, Inc. (US) 2025-08-06 EP claimed
CN-120153070-A Helicase-cytidine deaminase complexes and methods of use thereof 因美纳有限公司 2025-06-13 CN claimed
US-20250075176-A1 COMPOSITIONS COMPRISING HISTONE ACETYLTRANSFERASE INHIBITORS OR REVERSE TRANSCRIPTASE INHIBITORS AND USE THEREOF FOREVE LABS LTD. (IL) 2025-03-06 US claimed
EP-4490269-A1 COMPOSITIONS COMPRISING HISTONE ACETYLTRANSFERASE INHIBITORS OR REVERSE TRANSCRIPTASE INHIBITORS AND USE THEREOF Foreve Labs Ltd. (IL) 2025-01-15 EP claimed
US-20240240244-A1 Methylation Detection Method and Kit for Genomic DNA or Cell-Free DNA Molecules in Biological Sample ANCHORDX MEDICAL CO LTD (CN) 2024-07-18 US claimed
WO-2024118592-A2 METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 LONZA SALES AG (CH) 2024-06-06 WO claimed
WO-2024112937-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER AND METABOLIC DISEASE PRETZEL THERAPEUTICS, INC. (US) 2024-05-30 WO claimed
US-20240167036-A1 EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST LONZA SALES AG (CH) 2024-05-23 US claimed
WO-2004094616-A9 SILENCING TRANSCRIPTION BY METHYLATION GMR EPIGENETICS (US) 2005-03-31 WO claimed
WO-2004111266-A1 METHODS FOR GENOME AMPLIFICATION HUMAN GENETIC SIGNATURES PTY LTD (AU) 2004-12-23 WO claimed
WO-2004094616-A2 SILENCING TRANSCRIPTION BY METHYLATION GMR EPIGENETICS (US) 2004-11-04 WO claimed
US-20040204380-A1 Antisense modulation of novel anti-apoptotic bcl-2-related proteins ACKERMANN ELIZABETH J 2004-10-14 US claimed
WO-2004065625-A1 ASSAY FOR DETECTING METHYLATION CHANGES IN NUCLEIC ACIDS USING AN INTERCALATING NUCLEIC ACID HUMAN GENETIC SIGNATURES PTY LTD (AU) 2004-08-05 WO claimed
WO-2004003134-A2 ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA ISIS PHARMACEUTICALS, INC. (US) 2004-01-08 WO claimed
US-20040006036-A1 Silencing transcription by methylation GMR, A DELAWARE CORPORATION 2004-01-08 US claimed
EP-1325955-A1 Compounds and methods for the identification and/or validation of a target atugen AG (DE) 2003-07-09 EP claimed
US-6001992-A OLIGONUCLEOTIDES WHICH PROMOTE APOPTOSIS; ANTICARCINOGENIC AGENTS, VIRICIDES, AND TREATMENT OF AUTOIMMUNE DISORDERS ISIS PHARMACEUTICALS INC. (US) 1999-12-14 US claimed
EP-0133473-B1 In vivo labelling of polynucleotide sequences ENZO BIOCHEM INC (US) 1994-03-23 EP claimed